-
公开(公告)号：WO0204929A9
公开(公告)日：2002-11-07
申请号：PCT/CA0100992
申请日：2001-07-10
Applicant: UNIV HEALTH NETWORK , YANG VICTOR XIAO DONG , VITKIN I ALEX , WONGKEESONG LOUIE , KATZ SHARON , GORDON MARGARET LESLIE , WILSON BRIAN C , MOK ALVIN HO KWAN
Inventor： YANG VICTOR XIAO DONG , VITKIN I ALEX , WONGKEESONG LOUIE , KATZ SHARON , GORDON MARGARET LESLIE , WILSON BRIAN C , MOK ALVIN HO KWAN
CPC classification number: A61B5/6852 , A61B1/00096 , A61B1/00172 , A61B1/05 , A61B5/0066 , G01N21/4795
Abstract: A method and an apparatus for examining the sub-surface microstructure of a sample are provided. Radiation from a plurality of optical radiation sources travels along a first optical path. In the first optical path, a device focuses the optical radiation from each of the optical sources into a plurality of respective focal points along the first optical path to provide substantially continuous coverage of a selected portion of the first optical path. Then, a sample on the first optical path within the selected length extending into the sample is scanned along said selected portion of the first optical path.
Abstract translation: 提供了用于检查样本的表面微观结构的方法和设备。 来自多个光辐射源的辐射沿着第一光路传播。 在第一光路中，设备将来自每个光源的光辐射聚焦到沿着第一光路的多个相应焦点上，以提供对第一光路的选定部分的基本上连续的覆盖。 然后，沿着所述第一光路的所述选定部分扫描延伸到样本中的所选长度内的第一光路上的样本。
-
公开(公告)号：WO0179457A3
公开(公告)日：2002-09-06
申请号：PCT/CA0100512
申请日：2001-04-12
Applicant: UNIV HEALTH NETWORK , CHRISTENDAT DINESH , EDWARDS ALED M , PAI EMIL F , BOCHKAREV ALEXEI , SARIDAKIS VIVIAN
Inventor： CHRISTENDAT DINESH , EDWARDS ALED M , PAI EMIL F , BOCHKAREV ALEXEI , SARIDAKIS VIVIAN
CPC classification number: C12N9/90
Abstract: The invention provides the crystal structure of Methanobacterium thermoautotrophicum RmlC (MT RmlC) and identifies the active site thereof. The crystal structure can be used to determine the crystal structure of homologues, analogues, mutants and co-complexes of MT RmlC and to identify and design inhibitors to RmlC. The present invention has applicability in identifying and designing anti-bacterial agents and the treatment of bacterial infections.
Abstract translation: 本发明提供了甲醇杆菌RmlC（MT RmlC）的晶体结构，并鉴定了其活性位点。 晶体结构可用于确定MT RmlC的同系物，类似物，突变体和共配合物的晶体结构，并鉴定和设计RmlC抑制剂。 本发明适用于鉴定和设计抗菌剂和细菌感染的治疗。
-
公开(公告)号：WO0204929A2
公开(公告)日：2002-01-17
申请号：PCT/CA0100992
申请日：2001-07-10
Applicant: UNIV HEALTH NETWORK , YANG VICTOR XIAO DONG , VITKIN I ALEX , WONGKEESONG LOUIE , KATZ SHARON , GORDON MARGARET LESLIE , WILSON BRIAN C , MOK ALVIN HO KWAN
Inventor： YANG VICTOR XIAO DONG , VITKIN I ALEX , WONGKEESONG LOUIE , KATZ SHARON , GORDON MARGARET LESLIE , WILSON BRIAN C , MOK ALVIN HO KWAN
CPC classification number: A61B5/6852 , A61B1/00096 , A61B1/00172 , A61B1/05 , A61B5/0066 , G01N21/4795
Abstract: A method and an apparatus for examining the sub-surface microstructure of a sample are provided. Radiation from a plurality of optical radiation sources travels along a first optical path. In the first optical path, a device focuses the optical radiation from each of the optical sources into a plurality of respective focal points along the first optical path to provide substantially continuous coverage of a selected portion of the first optical path. Then, a sample on the first optical path within the selected length extending into the sample is scanned along said selected portion of the first optical path.
Abstract translation: 提供了一种用于检查样品的亚表面微观结构的方法和装置。 来自多个光辐射源的辐射沿着第一光路行进。 在第一光路中，设备将来自每个光源的光辐射沿着第一光路聚焦到多个相应的焦点中，以提供第一光路的选定部分的基本连续的覆盖。 然后，沿着第一光路的所选择的部分扫描在延伸到样本中的所选长度内的第一光路上的样本。
-
公开(公告)号：WO9955906A3
公开(公告)日：2000-03-16
申请号：PCT/CA9900377
申请日：1999-04-26
Applicant: UNIV HEALTH NETWORK , WOODGETT JAMES R , MANOUKIAN ARMEN S , JIN JING , WETSCH BEN
Inventor： WOODGETT JAMES R , MANOUKIAN ARMEN S , JIN JING , WETSCH BEN
IPC: A01K67/027 , C12N5/10 , C12N15/09 , C12Q1/68
CPC classification number: C12Q1/6897
Abstract: The present invention relates to cell death genes, which are genes required for programmed cell death; mutant organisms, in which ectopic programmed cell death occurs in embryos to a greater than normal extent and agents which alter the ability to modulate programmed cell death of cells. A mutant form of Daktl, Daktl?q? in a Drosophila melanogaster has been identified. Daktl and its mammalian homolog, PKB are known to protect cells from undergoing apoptosis. A genetic screen for identifying genes related to programmed cell death by their ability to interact genetically with the mutant form of Daktl is described.
Abstract translation: 本发明涉及细胞死亡基因，其是程序性细胞死亡所需的基因; 突变体生物，其中异位程序性细胞死亡发生在胚胎中大于正常程度，以及改变调节细胞程序性细胞死亡的能力的药剂。 Daktl的突变形式，Daktl？q？ 在果蝇中已被鉴定。 Daktl及其哺乳动物同源物PKB已知可以保护细胞免受细胞凋亡。 描述了通过其与遗传上与Dakt1的突变体形式进行相互作用的能力来鉴定与程序性细胞死亡有关的基因的遗传屏幕。
-
35.发明申请METHODS AND COMPOSITIONS FOR DETECTION OF TARGETS INVOLVED IN CANCER METASTASIS 审中-公开用于检测癌症参与的靶标的方法和组合物
公开(公告)号：WO2015132672A3
公开(公告)日：2015-12-17
申请号：PCT/IB2015000996
申请日：2015-03-06
Applicant: UNIV HEALTH NETWORK
Inventor： BLASER HEIKO , MAK TAK W
CPC classification number: C12Q1/6883 , A61K38/177 , A61K39/39541 , A61K39/39558 , A61K49/0008 , A61K2039/505 , A61K2039/507 , C07K14/70503 , C07K16/2818 , C07K2317/76 , C12N15/1135 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2320/30 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/5088 , G01N2333/82 , A61K2300/00
Abstract: The present application is directed to methods and compositions for identifying target nucleic acids that are involved in cancer metastasis. The method comprises transfecting an immortalized cell line with one or more target cDNAs, said transfected cells further expressing a detectable reporter gene. The immortalized cell line lacks metastatic potential in absence of the transfected target cDNAs. Upon injection of said transfected cells into an animal, tumor cells are imaged, isolated and analyzed with respect to the presence of said target cDNAs thus identifying a gene(s) that modulates tumor metastasis.
Abstract translation: 本申请涉及用于鉴定参与癌症转移的靶核酸的方法和组合物。 该方法包括用一种或多种靶cDNA转染永生化细胞系，所述转染细胞进一步表达可检测的报道基因。 在不存在转染的靶cDNA的情况下，永生化细胞系缺乏转移潜力。 在将所述转染的细胞注射到动物中后，相对于所述靶cDNA的存在，对肿瘤细胞进行成像，分离和分析，从而鉴定调节肿瘤转移的基因。
-
Patent Agency Ranking
公开(公告)号：WO2013136193A3
公开(公告)日：2014-01-16
申请号：PCT/IB2013001179
申请日：2013-03-14
Applicant: UNIV HEALTH NETWORK , TUSCHE MICHAEL W , MAK TAK W , OHASHI PAMELA S , LANG PHILIPP , LANG KARL , BRENNER DIRK , LIN GLORIA
Inventor： TUSCHE MICHAEL W , MAK TAK W , OHASHI PAMELA S , LANG PHILIPP , LANG KARL , BRENNER DIRK , LIN GLORIA
CPC classification number: C07K14/70503 , A61K38/1709 , A61K38/1774 , C07K14/705 , C07K2319/02 , C07K2319/30
Abstract: The present invention is further directed to methods and compositions for modulating the activity of the Toso protein. The invention further encompasses treatment of disorders associated with inflammation, autoimmune disorders, and cancer using compositions that include a soluble Toso protein.
Abstract translation: 本发明进一步涉及用于调节Toso蛋白活性的方法和组合物。 本发明还包括使用包括可溶性Toso蛋白的组合物治疗与炎症，自身免疫疾病和癌症相关的病症。
-
公开(公告)号：WO2006048877A3
公开(公告)日：2009-05-14
申请号：PCT/IL2005001154
申请日：2005-11-03
Applicant: FIBRON LTD , UNIV HEALTH NETWORK , YAYON AVNER , ROM ERAN , TRUDEL SUZANNE
Inventor： YAYON AVNER , ROM ERAN , TRUDEL SUZANNE
IPC: A61K39/395 , C07H21/04
CPC classification number: C07K16/2863 , A61K2039/505 , C07K2317/55 , C07K2317/622 , C07K2317/73 , C07K2317/76
Abstract: The present invention generally relates to a pharmaceutical composition and to an improved method of preventing, attenuating and treating multiple myeloma (MM) by administering to an individual in need thereof at least one antibody to fibroblast growth factor receptor 3 (FGFR3). In particular, the at least one FGR3 antibody induces apoptosis of myeloma cells expressing wild type FGFR3.
Abstract translation: 本发明一般涉及药物组合物和通过给需要的个体施用至少一种抗成纤维细胞生长因子受体3（FGFR3）的抗体来预防，减弱和治疗多发性骨髓瘤（MM）的改进方法。 特别地，至少一种FGR3抗体诱导表达野生型FGFR3的骨髓瘤细胞的凋亡。
-
公开(公告)号：WO2007038860A8
公开(公告)日：2007-12-21
申请号：PCT/CA2006001621
申请日：2006-10-03
Applicant: UNIV HEALTH NETWORK , KOTRA LAKSHMI P , PAI EMIL F
Inventor： KOTRA LAKSHMI P , PAI EMIL F
IPC: A61K31/7064 , A61P31/04 , A61P31/12 , C07H19/067 , C07H19/073
CPC classification number: C07H19/073 , C07H19/067
Abstract: The present invention includes the utility of anti-viral and/or antibacterial effective amounts of 6-substituted nucleoside derivatives of formula (I) (e.g. 6-iodouridine and 6-iodouridine monophosphate) in the treatment or prevention of viral infections (e.g. Flavivridae, Bunyaviridae, or Togaviridae, or viral infections of hepatitis C, hepatitis B, herpes, influenza, HIV, polio, Coxsackie A/B, rhino, small pox, Ebola, West Nile, or corona virus) and/or bacterial infections (e.g. H. pylori, S. Aureus, B. anthracis, Mycobacterial tuberculosis, M. leprae, M. avium, P. aueruginosa,
Abstract translation: 本发明包括抗病毒和/或抗菌有效量的式（I）的6-取代核苷衍生物（例如6-碘尿苷和6-碘尿苷单磷酸酯）用于治疗或预防病毒感染（例如黄病毒， 布尼亚病毒科或披膜病毒科或丙型肝炎，乙型肝炎，疱疹，流行性感冒，艾滋病毒，脊髓灰质炎，柯萨奇A / B，犀牛，小痘，埃博拉病毒，西尼罗河或电晕病毒）和/或细菌感染 幽门螺杆菌，金黄色葡萄球菌，炭疽杆菌，分枝杆菌结核分枝杆菌，麻疯病，鸟瘟，欧洲青蒿素，
-
公开(公告)号：WO2015066426A2
公开(公告)日：2015-05-07
申请号：PCT/US2014063347
申请日：2014-10-31
Applicant: REGENERON PHARMA , UNIV HEALTH NETWORK UHN
Inventor： PURCELL NGAMBO LISA ARLEEN , HIGGINS SARAH J , KAIN KEVIN C
IPC: A61K38/16
CPC classification number: A61K38/1891 , A61K31/357 , A61K31/365 , A61K31/49 , A61K38/16 , A61K38/17 , A61K38/18 , A61K38/1866 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K14/515 , C07K16/22 , C07K2319/30 , A61K2300/00
Abstract: The present invention provides methods for treating, preventing or reducing the severity of cerebral malaria. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a modified angiopoietin molecule such as AngF1-Fc-F1.
Abstract translation: 本发明提供了治疗，预防或降低脑疟疾严重程度的方法。 本发明的方法包括向有需要的受试者施用治疗有效量的包含修饰的血管生成素分子例如AngF1-Fc-F1的药物组合物。
-
40.发明申请
公开(公告)号：WO2014043223A8
公开(公告)日：2015-01-08
申请号：PCT/US2013059246
申请日：2013-09-11
Applicant: HOSPITAL FOR SPECIAL SURGERY , UNIV HEALTH NETWORK
Inventor： ISSUREE PRIYA , MARETZKY THORSTEN , MCILWAIN DAVID ROBERT , MAK TAK WAH , BLOBEL CARL , SALMON JANE
IPC: C07K16/18 , A61K39/395 , A61P37/00
CPC classification number: G01N33/573 , C07K16/18 , C07K16/2896 , C12Q1/37 , C12Q1/6876 , C12Q2600/136 , C12Q2600/158 , G01N2333/525 , G01N2333/705 , G01N2333/96486 , G01N2500/02 , G01N2500/10
Abstract: Disclosed are methods for treating a subject with a Complement mediated (e.g., C5a mediated) disease or an immune complex mediated disease. The method comprises the step of administering to the subject an effective amount of an agent that decreases the biological activity of iRhom2 or an agent that modulates formation of a complex between iRhom2 and TACE. Also disclosed are assays for identifying such agents.
Abstract translation: 公开了用补体介导的（例如C5a介导的）疾病或免疫复合物介导的疾病治疗受试者的方法。 该方法包括向受试者施用有效量的降低iRhom2的生物学活性的试剂或调节iRhom2和TACE之间的复合物形成的试剂的步骤。 还公开了用于鉴定这种试剂的测定法。
-
-
-
-
-
-
-
-
-
Search Results
1009
records
(took 0.023 seconds)
